

# Jan Sperl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1734174/publications.pdf>

Version: 2024-02-01

67  
papers

7,003  
citations

318942

23  
h-index

175968

55  
g-index

69  
all docs

69  
docs citations

69  
times ranked

6635  
citing authors

#	ARTICLE	IF	CITATIONS
1	HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons. <i>Viruses</i> , 2022, 14, 482.	1.5	9
2	Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis. <i>PLoS ONE</i> , 2021, 16, e0244934.	1.1	6
3	Is elimination of HCV in 2030 realistic in Central Europe. <i>Liver International</i> , 2021, 41, 56-60.	1.9	9
4	Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. <i>Harm Reduction Journal</i> , 2021, 18, 69.	1.3	16
5	Portal hypertension is the main driver of liver stiffness in advanced liver cirrhosis. <i>Physiological Research</i> , 2021, 70, 563-577.	0.4	7
6	Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10560.	1.8	8
7	Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics. <i>International Journal of Public Health</i> , 2020, 65, 1723-1735.	1.0	0
8	How close are we to hepatitis C virus elimination in Central Europe?. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 1-8.	0.6	11
9	PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age. <i>PLoS ONE</i> , 2019, 14, e0222609.	1.1	3
10	IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post- $\epsilon$ prophylaxis and late period. <i>Transplant Infectious Disease</i> , 2019, 21, e13124.	0.7	5
11	&lt;p&gt;Elbasvir/grazoprevir&lt;/p&gt; in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy&lt;/p&gt;. <i>International Journal of Women's Health</i> , 2019, Volume 11, 617-628.	1.1	2
12	Chronic hepatitis C in the Czech Republic: Forecasting the disease burden. <i>Central European Journal of Public Health</i> , 2019, 27, 93-98.	0.4	4
13	Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study. <i>Digestive and Liver Disease</i> , 2018, 50, 490-495.	0.4	25
14	Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 594-605.	0.9	20
15	The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. <i>Journal of Gastroenterology</i> , 2018, 53, 679-688.	2.3	43
16	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 125-133.	3.7	128
17	Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2631-2638.	0.8	7
18	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	3.7	208

#	ARTICLE	IF	CITATIONS
19	Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 733-738.	0.9	15
20	Direct-acting antivirals in the treatment of HCV-associated malignant lymphomas. <i>Gastroenterologie A Hepatologie</i> , 2017, 71, 138-144.	0.0	1
21	Clinical practice guidelines for chronic hepatitis C virus infection. <i>Gastroenterologie A Hepatologie</i> , 2017, 71, 117-136.	0.0	0
22	Czech Society of Hepatology guidelines for diagnosis and treatment of acute porphyrias. <i>Gastroenterologie A Hepatologie</i> , 2017, 71, 101-104.	0.0	0
23	Hepatology topics of special interest from Central Europe (Czech Republic, Hungary, Poland.) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10</i>	0.8	0
24	Sa1600 Treatment of Uncontrollable Acute Variceal Bleeding With Self-Expanding Metal Stent: A Single Center Experience. <i>Gastroenterology</i> , 2016, 150, S339.	0.6	2
25	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	3.6	550
26	Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. <i>Journal of Hepatology</i> , 2016, 65, 1112-1119.	1.8	45
27	Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2016, 64, 574-582.	1.8	196
28	Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. <i>Hepatology</i> , 2015, 62, 243-252.	3.6	493
29	Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load ( $\geq 9 \log_{10}$ copies/ml). <i>Liver International</i> , 2015, 35, 422-428.	1.9	6
30	USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1853.	0.9	2
31	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840.	1.8	289
32	Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2015, 21, 5496.	1.4	8
33	Standard diagnostic and therapeutic approaches to chronic hepatitis C virus infection. <i>Gastroenterologie A Hepatologie</i> , 2015, 69, .	0.0	0
34	Strategies to manage hepatitis C virus (HCV) disease burden. <i>Journal of Viral Hepatitis</i> , 2014, 21, 60-89.	1.0	161
35	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , 2014, 21, 34-59.	1.0	372
36	Historical epidemiology of hepatitis C virus (HCV) in selected countries. <i>Journal of Viral Hepatitis</i> , 2014, 21, 5-33.	1.0	211

#	ARTICLE	IF	CITATIONS
37	Genetic variation in TNFA predicts protection from severe bacterial infections in patients with end-stage liver disease awaiting liver transplantation. <i>Journal of Hepatology</i> , 2014, 60, 773-781.	1.8	7
38	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	1.8	741
39	Incidental Hepatocellular Carcinoma: Risk Factors and Long-Term Outcome After Liver Transplantation. <i>Transplantation Proceedings</i> , 2014, 46, 1426-1429.	0.3	23
40	<i>ABC B4</i> mutations underlie hormonal cholestasis but not pediatric idiopathic gallstones. <i>World Journal of Gastroenterology</i> , 2014, 20, 5867.	1.4	21
41	Standard diagnostic and therapeutic procedure for chronic infection of hepatitis C virus. <i>Gastroenterologie A Hepatologie</i> , 2014, 68, 499-512.	0.0	0
42	Recommended procedure for diagnosis and treatment of chronic hepatitis B. <i>Gastroenterologie A Hepatologie</i> , 2014, 68, 514-526.	0.0	2
43	Further evidence of the benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2013, 58, 833-835.	1.8	3
44	Urgent Liver Transplantation for Chemotherapy-Induced HBV Reactivation: A Suitable Option in Patients Recently Treated for Malignant lymphoma. <i>Transplantation Proceedings</i> , 2013, 45, 2834-2837.	0.3	9
45	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1426-1437.e9.	0.6	2,211
46	Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. <i>Hepatology</i> , 2013, 58, 505-513.	3.6	104
47	FAT MASS AND OBESITY-ASSOCIATED (FTO) GENE AND ALCOHOL INTAKE. <i>Addiction</i> , 2012, 107, 1185-1186.	1.7	7
48	Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. <i>Journal of Viral Hepatitis</i> , 2012, 19, 537-546.	1.0	62
49	De novo Malignancies After Orthotopic Liver Transplantation (OLT) Do Not Compromise the Outcome. <i>Gastroenterology</i> , 2011, 140, S-962.	0.6	0
50	Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. <i>Hepatology</i> , 2010, 52, 1201-1207.	3.6	63
51	Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection. <i>Gastroenterology</i> , 2010, 138, 1365-1373.e2.	0.6	86
52	Do common genetic variants in endotoxin signaling pathway contribute to predisposition to alcoholic liver cirrhosis?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 398-404.	1.4	10
53	N-acetyl cysteine averted liver transplantation in a patient with liver failure caused by erythropoietic protoporphyria. <i>Liver Transplantation</i> , 2009, 15, 352-354.	1.3	7
54	Frequent and Various Biliary Complications Did Not Compromise the Outcome of Orthotopic Liver Transplantation (OLT): Ten Years Experience with 500 Consecutive Patients. <i>Gastrointestinal Endoscopy</i> , 2008, 67, AB170.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Acute rejection of non-functional allograft in kidney transplant recipients with hepatitis C treated with peginterferon- $\alpha$ 2a. <i>Journal of Hepatology</i> , 2008, 49, 461-462.	1.8	5
56	72 TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B: WEEK 72 TDF DATA AND WEEK 24 ADEFOVIR DIPIVOXIL SWITCH DATA (STUDY 103). <i>Journal of Hepatology</i> , 2008, 48, S32.	1.8	31
57	877 TEMPORARY NASOBILIARY DRAINAGE INDUCES RELIEF FROM SEVERE LONG-LASTING PRURITUS IN DRUG-INDUCED CANALICULAR CHOLESTASIS. <i>Journal of Hepatology</i> , 2008, 48, S329.	1.8	0
58	888 IMPROVEMENT OF LIVER DYSFUNCTION AFTER TREATMENT WITH N-ACETYL CYSTEINE IN PATIENT WITH ERYTHROPOIETIC PROTOPORHYRIA. <i>Journal of Hepatology</i> , 2008, 48, S333.	1.8	0
59	Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. <i>Hepatology</i> , 2008, 47, 1604-1614.	3.6	266
60	The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A.. <i>Current Medical Research and Opinion</i> , 2008, 24, 1943-1950.	0.9	5
61	[751] HIGH SECRETORY HAPLOTYPE OF INTERLEUKIN-1 GENE CLUSTER INCREASES THE RISK OF ALCOHOLIC LIVER CIRRHOSIS. <i>Journal of Hepatology</i> , 2007, 46, S282.	1.8	0
62	Revised King's College score for liver transplantation in adult patients with Wilson's disease. <i>Liver Transplantation</i> , 2007, 13, 55-61.	1.3	51
63	Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. <i>Journal of Hepatology</i> , 2006, 44, 97-103.	1.8	418
64	Liver Transplantation in Eastern Europe. <i>Liver Transplantation</i> , 2000, 6, 665-669.	1.3	6
65	Liver transplantation for fulminant Wilson's disease, the significance of prothrombin time on admission. <i>Gastroenterology</i> , 2000, 118, A1495.	0.6	0
66	Use of $^{31}\text{P}$ MR spectroscopy in liver cirrhosis. <i>Journal of Hepatology</i> , 2000, 32, 156.	1.8	1
67	The process of continuous production and isolation of coproporphyrin. <i>Biotechnology Letters</i> , 1988, 10, 273-276.	1.1	0